Value of SERMs in Postmenopausal Women
Carlo Palmieri,Eric W-F Lam,David Vigushin,R Charles Coombes
DOI: https://doi.org/10.1016/s0140-6736(04)16118-7
2004-01-01
Abstract:The HABITS study (Feb 7, p 453),1Holmberg L Anderson H for the HABITS steering and data monitoring committeesHABITS (hormone replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped.Lancet. 2004; 363: 4531-4555Google Scholar along with other studies, clearly shows the potential detrimental effects of hormone replacement therapy (HRT) on women's health. The time has therefore come to move away from HRT to a treatment based on our molecular knowledge of the target for HRT—ie, oestrogen receptors α and β. Selective oestrogen-receptor modulators (SERMs) are the first generation of post-HRT therapeutic agents that offer the possibility of maintaining the health of postmenopausal women while avoiding the breast and other related problems encountered with HRT.SERMs are non-steroidal compounds with tissue-specific agonist-antagonist activity, and currently available SERMs include tamoxifen, raloxifene, and toremifene. A failed breast cancer drug, raloxifene was seen to maintain bone density in ovariectomised rats while avoiding the oestrogenic effect on the uterus seen with tamoxifen.2Jensen EV Jordan VC The estrogen receptor: a model for molecular medicine.Clin Cancer Res. 2003; 9: 1980-1989PubMed Google Scholar This finding eventually led to the Multiple Outcomes of Raloxifene Evaluation (MORE) study3Ettinger B Black DM Mitlak BH et al.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomised clinical trial.JAMA. 1999; 282: 637-645Crossref PubMed Scopus (3071) Google Scholar in osteoporotic postmenopausal women, which revealed that raloxifene could increase bone-mineral density and reduce the risk of spinal fracture by 30–50% compared with placebo. Additionally, there was a 76% reduction in the incidence of invasive breast cancer with no increase in the risk of endometrial carcinoma seen with tamoxifen. However, there was an increase in thromboembolic disease, similar in magnitude to that seen with tamoxifen and HRT.4Cummings SR Eckert S Krueger KA et al.The effects of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial.JAMA. 1999; 281: 2189-2197Crossref PubMed Scopus (1836) Google ScholarCurrently raloxifene is being investigated in a double-blind randomised controlled trial known as Raloxifene Use for The Heart (RUTH).5Mosca L Barrett-Connor E Wenger NK et al.Design and methods of the Raloxifene use for the heart (RUTH) study.Am J Cardiol. 2001; 4: 392-395Summary Full Text Full Text PDF Scopus (181) Google Scholar This trial involves 10 000 postmenopausal women with coronary heart disease (CHD), peripheral arterial disease, or multiple risk factors for CHD, with the primary endpoint being the number of coronary events. This trial aims to provide information on the cardiovascular benefit of a SERM in postmenopausal women at high risk of CHD, which is particularly important in view of the cardiovascular complications seen with HRT.The unique properties of SERMs lie in their bulky side-chain, which prevents helix 12 of the oestrogen receptor relocating over the ligand-binding pocket as it would if oestrogen were bound. This blocking effect in turn prevents key coregulator proteins (known as co activators) from interacting with the receptor and thus prevents activation. The further differences seen between tamoxifen and raloxifene in relation to their oestrogenic and antioestrogenic properties relates to the ability of the raloxifene side-chain to interact closely with aminoacid 351, thus further influencing the function of the oestrogen receptor.2Jensen EV Jordan VC The estrogen receptor: a model for molecular medicine.Clin Cancer Res. 2003; 9: 1980-1989PubMed Google ScholarImprovements in our molecular knowledge regarding the distribution, functioning, and modulation of oestrogen receptors α and β in different target organs, and the relative contribution of each receptor type to the normal functioning of each organ, will lead to the development of organ-specific and receptor-specific SERMs, as well as novel classes of drugs, such as those targeting the coregulators (coactivators and corepressors). Although many questions remain unanswered about SERMs, and their role is still limited, they have provided proof of principle and represent the first steps away from current HRT to an era of molecular-based postmenopausal therapy. The HABITS study (Feb 7, p 453),1Holmberg L Anderson H for the HABITS steering and data monitoring committeesHABITS (hormone replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped.Lancet. 2004; 363: 4531-4555Google Scholar along with other studies, clearly shows the potential detrimental effects of hormone replacement therapy (HRT) on women's health. The time has therefore come to move away from HRT to a treatment based on our molecular knowledge of the target for HRT—ie, oestrogen receptors α and β. Selective oestrogen-receptor modulators (SERMs) are the first generation of post-HRT therapeutic agents that offer the possibility of maintaining the health of postmenopausal women while avoiding the breast and other related problems encountered with HRT. SERMs are non-steroidal compounds with tissue-specific agonist-antagonist activity, and currently available SERMs include tamoxifen, raloxifene, and toremifene. A failed breast cancer drug, raloxifene was seen to maintain bone density in ovariectomised rats while avoiding the oestrogenic effect on the uterus seen with tamoxifen.2Jensen EV Jordan VC The estrogen receptor: a model for molecular medicine.Clin Cancer Res. 2003; 9: 1980-1989PubMed Google Scholar This finding eventually led to the Multiple Outcomes of Raloxifene Evaluation (MORE) study3Ettinger B Black DM Mitlak BH et al.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomised clinical trial.JAMA. 1999; 282: 637-645Crossref PubMed Scopus (3071) Google Scholar in osteoporotic postmenopausal women, which revealed that raloxifene could increase bone-mineral density and reduce the risk of spinal fracture by 30–50% compared with placebo. Additionally, there was a 76% reduction in the incidence of invasive breast cancer with no increase in the risk of endometrial carcinoma seen with tamoxifen. However, there was an increase in thromboembolic disease, similar in magnitude to that seen with tamoxifen and HRT.4Cummings SR Eckert S Krueger KA et al.The effects of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial.JAMA. 1999; 281: 2189-2197Crossref PubMed Scopus (1836) Google Scholar Currently raloxifene is being investigated in a double-blind randomised controlled trial known as Raloxifene Use for The Heart (RUTH).5Mosca L Barrett-Connor E Wenger NK et al.Design and methods of the Raloxifene use for the heart (RUTH) study.Am J Cardiol. 2001; 4: 392-395Summary Full Text Full Text PDF Scopus (181) Google Scholar This trial involves 10 000 postmenopausal women with coronary heart disease (CHD), peripheral arterial disease, or multiple risk factors for CHD, with the primary endpoint being the number of coronary events. This trial aims to provide information on the cardiovascular benefit of a SERM in postmenopausal women at high risk of CHD, which is particularly important in view of the cardiovascular complications seen with HRT. The unique properties of SERMs lie in their bulky side-chain, which prevents helix 12 of the oestrogen receptor relocating over the ligand-binding pocket as it would if oestrogen were bound. This blocking effect in turn prevents key coregulator proteins (known as co activators) from interacting with the receptor and thus prevents activation. The further differences seen between tamoxifen and raloxifene in relation to their oestrogenic and antioestrogenic properties relates to the ability of the raloxifene side-chain to interact closely with aminoacid 351, thus further influencing the function of the oestrogen receptor.2Jensen EV Jordan VC The estrogen receptor: a model for molecular medicine.Clin Cancer Res. 2003; 9: 1980-1989PubMed Google Scholar Improvements in our molecular knowledge regarding the distribution, functioning, and modulation of oestrogen receptors α and β in different target organs, and the relative contribution of each receptor type to the normal functioning of each organ, will lead to the development of organ-specific and receptor-specific SERMs, as well as novel classes of drugs, such as those targeting the coregulators (coactivators and corepressors). Although many questions remain unanswered about SERMs, and their role is still limited, they have provided proof of principle and represent the first steps away from current HRT to an era of molecular-based postmenopausal therapy.